Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])

Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL]) - Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028130

Enrollment

200

Registered

2017-07-07

Start date

2016-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory mantle cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with rrMCL who administered IMBRUVICA

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness	—

Countries

Japan

Contacts

Public ContactFumi Nomura

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

fnomura@ITS.JNJ.com03-4411-8110

Outcome results